Table 4 Antimalarial activity of pMCM-41 encapsulated QN (2) in P. berghei NK65-infected mice.
From: Mesoporous silica nanocarriers encapsulated antimalarials with high therapeutic performance
Dose (mg/kg bw) | Parasitemia (% Reduction) | Mean Survival Time (Days) | ||
|---|---|---|---|---|
Day 4 post-inoculation | Day 6 post-inoculation | Day 8 post-inoculation | ||
Infected Untreated | 2.81 | 3.61 | 9.60 | 7.75 |
QN2 (15) | 0.90(67.97) | 0.98(73.13) | 2.30(76.04) | 20.50 |
0.0625 | 2.59(7.83) | 1.14(68.42) | 1.63(83.02) | 16.50 |
0.125 | 2.58(8.19) | 0.55(84.76) | 2.86(70.21) | 16.50 |
0.25 | 1.59(43.42) | 0.69(80.89) | 1.43(85.10) | 20.50 |
0.50 | 0.87(69.04) | 0.73(79.78) | 12.13(26.35) | 13.25 |
1.00 | 0.51(81.85) | 0.69(80.89) | 1.24(87.08) | 17.50 |
